Hennig L
Clin Nephrol. 2003 Jul;60 Suppl 1:S53-8.
The clinical value of inhibition of the renin-angiotensin-aldosterone-system (RAAS) in heart failure has clearly been documented for the ACE-inhibitors as well as for the angiotensin-I-receptor blocker (AT1) by extensive intervention studies (AIRE, CONSENSUS, SAVE, ELITE II, ValHeFT and others). The additional specific vascular and renal protection, acting beyond the lowering of blood pressure, has been investigated in the past years in numerous studies in patients with arterial hypertension, often accompanied by diabetes mellitus type II. Whereas for nephroprotection, especially also in additionally present diabetes mellitus type II, study results clearly support the assumption of additional protective effects, which exceed the purely blood-pressure lowering effect; the data available for vascular protection (coronary and cerebral vessels) are insufficient.
通过广泛的干预研究（AIRE、CONSENSUS、SAVE、ELITE II、ValHeFT等），已明确证明抑制肾素-血管紧张素-醛固酮系统（RAAS）在心力衰竭治疗中的临床价值，这对于ACE抑制剂以及血管紧张素I受体阻滞剂（AT1）均适用。过去几年，在众多伴有II型糖尿病的动脉高血压患者中开展了大量研究，探究了其在降低血压之外的额外特异性血管和肾脏保护作用。对于肾脏保护，尤其是在同时存在II型糖尿病的情况下，研究结果明确支持存在超出单纯降压作用的额外保护作用这一假设；而关于血管保护（冠状动脉和脑血管）的现有数据并不充分。
